Last Updated:
10 Mar 2026, 03:29:53 PM (IST)
Ind-Swift Laboratories Limited
NSE: INDSWFTLAB BSE: INDSWFTLAB
NSE
142.63
2.83 (2.02%)
Prev Close
139.8
Open Price
142.46
Volume
401,313
Today Low / High
140.59 / 145.7
52 WK Low / High
68.72 / 151.98
Range
135 - 150
BSE
142.25
2.65 (1.90%)
Prev Close
139.6
Open Price
142.95
Volume
16,438
Today Low / High
141.1 / 145.45
52 WK Low / High
67.15 / 151.95
Range
135 - 149
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 142.63 (target range: 135 - 150), reflecting a change of 2.83 (2.02432%). On the BSE, it is listed at 142.25 (target range: 135 - 149), showing a change of 2.65 (1.89828%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Ind-Swift Laboratories Limited Graph
Ind-Swift Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Ind-Swift Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 142.63, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 142.25 | 143.67 | 129.31 - 158.04 |
| 145.10 | 116.08 - 174.11 | ||
| 146.52 | 102.56 - 190.47 | ||
| Bearish Scenario | 142.25 | 140.83 | 126.74 - 154.91 |
| 139.41 | 111.52 - 167.29 | ||
| 137.98 | 96.59 - 179.38 |
Overview of Ind-Swift Laboratories Limited
ISIN
INE915B01019
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
463,803
Market Cap
11,956,093,247
Last Dividend
0
Official Website
IPO Date
2002-07-01
DCF Diff
49.67
DCF
97
Financial Ratios Every Investor Needs
Stock Dividend of INDSWFTLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2011-09-20 | September 20, 11 | 1 | 1 | 2011-09-21 | 2011-10-26 | 2011-05-25 |
| 2010-09-16 | September 16, 10 | 1 | 1 | 2010-09-18 | 2010-10-22 | 2010-05-29 |
| 2009-09-17 | September 17, 09 | 1 | 1 | 2009-09-19 | 2009-10-24 | 2009-06-29 |
| 2008-09-18 | September 18, 08 | 1 | 1 | 2008-09-22 | 2008-11-01 | 2008-06-19 |
| 2007-09-21 | September 21, 07 | 1 | 1 | 2007-09-25 | 2007-11-01 | 2007-07-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 561.71 Cr | 287.95 Cr | 273.76 Cr | 0.4874 | 2.30 Cr | 119.16 Cr | -43.87 Cr | 250.48 Cr | 37.25 | 285.20 Cr | 0.4459 |
| 2024-03-31 | 1,280.90 Cr | 867.58 Cr | 413.32 Cr | 0.3227 | 35.52 Cr | 36.78 Cr | 200.90 Cr | 420.96 Cr | 91.18 | 782.41 Cr | 0.3286 |
| 2023-03-31 | 1,207.31 Cr | 766.86 Cr | 440.45 Cr | 0.3648 | 42.57 Cr | 20.52 Cr | 181.52 Cr | 47.60 Cr | 8.06 | 235.77 Cr | 0.0394 |
| 2022-03-31 | 1,038.73 Cr | 629.12 Cr | 409.61 Cr | 0.3943 | 32.72 Cr | 20.41 Cr | 92.42 Cr | -2.15 Cr | -0.36 | 235.02 Cr | -0.0021 |
| 2021-03-31 | 891.34 Cr | 516.24 Cr | 375.10 Cr | 0.4208 | 33.01 Cr | 15.95 Cr | 110.96 Cr | -3.15 Cr | -0.53 | 198.25 Cr | -0.0035 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 428.04 Cr | 1,438.34 Cr | 265.37 Cr | 1,172.9997 Cr | 40.84 Cr | -387.20 Cr | 114.18 Cr | 260.07 Cr | 0.00 Cr | 0.00 Cr | 252.00 Cr | 220.5801 Cr |
| 2024-03-31 | 493.81 Cr | 1,460.43 Cr | 648.37 Cr | 936.1773 Cr | 16.62 Cr | -415.31 Cr | 108.73 Cr | 5.36 Cr | 5.35 Cr | 0.00 Cr | 110.54 Cr | 216.5571 Cr |
| 2023-03-31 | 18.20 Cr | 1,824.06 Cr | 1,142.13 Cr | 681.9307 Cr | 862.10 Cr | 843.90 Cr | 438.60 Cr | 592.75 Cr | 0.00 Cr | 0.12 Cr | 25.38 Cr | 371.0889 Cr |
| 2022-03-31 | 21.48 Cr | 1,800.79 Cr | 1,199.93 Cr | 600.9723 Cr | 953.02 Cr | 931.54 Cr | 428.50 Cr | 636.84 Cr | 0.00 Cr | 0.15 Cr | 29.06 Cr | 334.4653 Cr |
| 2021-03-31 | 11.60 Cr | 1,818.45 Cr | 1,215.03 Cr | 603.5061 Cr | 1,005.35 Cr | 993.75 Cr | 375.67 Cr | 748.09 Cr | 0.00 Cr | 0.17 Cr | 27.23 Cr | 314.5231 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -25.4735 Cr | -109.6222 Cr | 69.2046 Cr | -89.8796 Cr | -66.4687 Cr | 427.4607 Cr | -64.4061 Cr | 34.5943 Cr | 20.9929 Cr | 0.0000 Cr | -43.1578 Cr |
| 2024-03-31 | -163.1152 Cr | -122.6903 Cr | 698.9138 Cr | -207.6321 Cr | 413.2799 Cr | 431.4797 Cr | -44.5169 Cr | 420.9616 Cr | -37.4278 Cr | 0.0000 Cr | 32.8866 Cr |
| 2023-03-31 | 194.6196 Cr | -13.3683 Cr | -185.6574 Cr | 181.8489 Cr | -4.4061 Cr | 17.0715 Cr | -12.7707 Cr | 113.1690 Cr | -45.9089 Cr | 0.0000 Cr | -10.1029 Cr |
| 2022-03-31 | 150.2741 Cr | 4.7722 Cr | -140.8769 Cr | 131.8592 Cr | 14.1694 Cr | 25.7700 Cr | -18.4149 Cr | 12.5324 Cr | -36.0118 Cr | 0.0000 Cr | -52.8337 Cr |
| 2021-03-31 | 134.9471 Cr | -10.1716 Cr | -123.7469 Cr | 130.5505 Cr | 1.0287 Cr | 11.6110 Cr | -3.9104 Cr | 18.0085 Cr | -39.8529 Cr | 0.0000 Cr | -32.8484 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 150.85 Cr | 111.03 Cr | 39.82 Cr | 0.2640 | -4.66 Cr | 9.54 Cr | 1.17 | 4.18 Cr | 0.0632 |
| 2025-09-30 | 152.64 Cr | 77.65 Cr | 74.99 Cr | 0.4913 | -5.50 Cr | 7.99 Cr | 1.00 | 19.34 Cr | 0.0523 |
| 2025-06-30 | 152.73 Cr | 73.09 Cr | 79.65 Cr | 0.5215 | 47.11 Cr | 8.77 Cr | 1.28 | 3.04 Cr | 0.0574 |
| 2025-03-31 | 507.92 Cr | 246.11 Cr | 261.82 Cr | 0.5155 | -7.09 Cr | 249.12 Cr | 42.16 | 283.31 Cr | 0.4905 |
| 2024-12-31 | 8.66 Cr | 6.22 Cr | 2.45 Cr | 0.2822 | -14.78 Cr | 0.01 Cr | 0.00 | -0.72 Cr | 0.0007 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 399.93 Cr | 33.53 Cr | 433.46 Cr | 175.27 Cr | 108.58 Cr | 843.81 Cr | 271.44 Cr | 1,544.43 Cr | 236.99 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 467.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,172.96 Cr |
| 2025-03-31 | 428.04 Cr | 39.37 Cr | 481.64 Cr | 164.52 Cr | 114.18 Cr | 865.35 Cr | 260.07 Cr | 1,438.34 Cr | 265.37 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 438.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,011.52 Cr |
| 2024-09-30 | 438.46 Cr | 0.00 Cr | 438.46 Cr | 57.55 Cr | 9.33 Cr | 586.80 Cr | 5.02 Cr | 1,188.02 Cr | 176.50 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 8.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 249.12 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 0.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 0.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 0.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Vice President of HR
Akashdeep Sharma
Gender: Not Specified
Year Born:
Vice President of Accounts
Lalit Goyal
Gender: Not Specified
Year Born:
Chief Financial Officer
Gagan Aggarwal
Gender: male
Year Born:
Joint MD & Whole Time Director
Himanshu Jain
Gender: male
Year Born: 1982
Chairman & MD
Navrattan Munjal
Gender: male
Year Born: 1952
Vice President of Corporate Affairs, Compliance Officer & Company Secretary
Pardeep Verma
Gender: male
Year Born:
Executive Director
Rishav Mehta
Gender: male
Year Born: 1991
Executive Director
Sahil Munjal
Gender: male
Year Born: 1980
Senior Vice President of Marketing
Varun Chhabra
Gender: Not Specified
Year Born:
Chief Operating Officer
Anil Ratanlal Agrawal
Gender: Not Specified
Year Born:
FAQs about Ind-Swift Laboratories Limited
Who is the CEO of the company?
The CEO is Navrattan R. Munjal.
What is the current market price of the stock?
The current price is ₹146.50.
What is the 52-week price range?
The range is ₹68.72-149.9.
What is the market capitalization of the company?
The market capitalization is ₹1,195.61 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 4.34.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Ind-Swift Laboratories Limited (ISIN: INE915B01019) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,195.61 crores and an average daily volume of 463,803 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.